Comprehensive Review of Candidozyma (Candida) auris Management: Insights From the Society of Infectious Diseases Pharmacists - PubMed
5 hours ago
- #Infection control
- #Antifungal resistance
- #Candida auris
- Candidozyma (Candida) auris is a multidrug-resistant fungal pathogen posing a global health threat.
- Reclassified into the genus Candidozyma, it thrives in healthcare environments due to heat, salinity, and disinfectant tolerance.
- Biofilm formation enhances its virulence and resistance to antifungal treatments.
- Clinical outcomes range from colonization to invasive infections with ~50% mortality rates.
- Echinocandins are first-line but face limitations like fungistatic activity and emerging resistance.
- Triazoles and amphotericin B are less effective due to resistance and toxicity.
- Newer agents (ibrexafungerp, fosmanogepix, rezafungin) show promise but lack clinical data.
- Infection control relies on surveillance, contact precautions, and effective disinfection.
- Decolonization strategies are inadequate, leading to recurrence and transmission challenges.
- Ongoing research focuses on optimized therapy, rapid diagnostics, and improved infection control.